[1] WITKOŚ J, HARTMAN-PETRYCKA M. Will future doctors know enough about stress urinary incontinence to provide proper preventive measures and treatment? Med Educ Online. 2019;24(1):1685635.
[2] 中华医学会妇产科学分会妇科盆底学组.女性压力性尿失禁诊断和治疗指南[J].中华妇产科杂志,2017,52(5):289-293.
[3] BILLECOCQ S, BO K, DUMOULIN C, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and non-pharmacological management of female pelvic floor dysfunction. Prog Urol. 2019;29(4):183-208.
[4] ARAGÓN IM, IMBRODA BH, LARA MF. Cell Therapy Clinical Trials for Stress Urinary Incontinence: Current Status and Perspectives. Int J Med Sci. 2018;15(3):195-204.
[5] KOMESU YM, SCHRADER RM, KETAI LH, et al. Epidemiology of mixed, stress, and urgency urinary incontinence in middle-aged/older women: the importance of incontinence history. Int Urogynecol J. 2016;27(5): 763-772.
[6] HOYLAND K, VASDEV N, ABROF A, et al. Post-radical prostatectomy incontinence: etiology and prevention. Rev Urol. 2014;16(4):181-188.
[7] ZHU L, LANG J, LIU C, et al. The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause. 2009;16(4):831-836.
[8] CUI L, MENG Q, WEN J, et al. A Functional Comparison of Treatment of Intrinsic Sphincter Deficiency with Muscle-Derived and Adipose Tissue-Derived Stem Cells. IUBMB Life. 2018;70(10):976-984.
[9] BENNINGTON J, WILLIAMS JK, ANDERSSON KE. New concepts in regenerative medicine approaches to the treatment of female stress urinary incontinence. Curr Opin Urol. 2019;29(4):380-384.
[10] HILLARY CJ, ROMAN S, MACNEIL S, et al. Regenerative medicine and injection therapies in stress urinary incontinence. Nat Rev Urol. 2020;17(3):151-161.
[11] ZORDANI A, PISCIOTTA A, BERTONI L, et al. Regenerative potential of human dental pulp stem cells in the treatment of stress urinary incontinence: In vitro and in vivo study. Cell Prolif. 2019;52(6):e12675.
[12] CICCOCIOPPO R, CANTORE A, CHAIMOV D, et al. Regenerative medicine: the red planet for clinicians. Intern Emerg Med. 2019;14(6): 911-921.
[13] VINAROV A, ATALA A, YOO J, et al. Cell therapy for stress urinary incontinence: Present-day frontiers. J Tissue Eng Regen Med. 2018; 12(2):e1108-e1121.
[14] BLAIVAS JG, PUROHIT RS, BENEDON MS, et al. Safety considerations for synthetic sling surgery. Nat Rev Urol. 2015;12(9):481-509.
[15] ZAMBON JP, WILLIAMS KJ, BENNINGTON J, et al. Applicability of regenerative medicine and tissue engineering for the treatment of stress urinary incontinence in female patients. Neurourol Urodyn. 2019;38 Suppl 4:S76-S83.
[16] KOZLOWSKA U, KRAWCZENKO A, FUTOMA K, et al. Similarities and differences between mesenchymal stem/progenitor cells derived from various human tissues. World J Stem Cells. 2019;11(6):347-374.
[17] THURNER M, DEUTSCH M, JANKE K, et al. Generation of myogenic progenitor cell-derived smooth muscle cells for sphincter regeneration. Stem Cell Res Ther. 2020;11(1):233.
[18] YASEEN MM, ABUHARFEIL NM, DARMANI H, et al. Recent advances in myeloid-derived suppressor cell biology. Front Med. 2020 Sep 2. doi: 10.1007/s11684-020-0797-2. Online ahead of print.
[19] JANKOWSKI RJ, TU LM, CARLSON C, et al. A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. Int Urol Nephrol. 2018;50(12):2153-2165.
[20] MUSAVI L, BRANDACHER G, HOKE A, et al. Muscle-derived stem cells: important players in peripheral nerve repair. Expert Opin Ther Targets. 2018;22(12):1009-1016.
[21] WANG Y, XU H, LIU X, et al. Inhibition of fibroblast differentiation of muscle-derived stem cells in cell implantation treatment of stress urinary incontinence. Cell Reprogram. 2011;13(5):459-464.
[22] TAMAKI T, UCHIYAMA Y, HIRATA M, et al. Therapeutic isolation and expansion of human skeletal muscle-derived stem cells for the use of muscle-nerve-blood vessel reconstitution. Front Physiol. 2015;6:165.
[23] KWON D, MINNERY B, KIM Y, et al. Neurologic recovery and improved detrusor contractility using muscle-derived cells in rat model of unilateral pelvic nerve transection. Urology. 2005;65(6):1249-1253.
[24] PRAUD C, SEBE P, BIÉRINX AS, et al. Improvement of urethral sphincter deficiency in female rats following autologous skeletal muscle myoblasts grafting. Cell Transplant. 2007;16(7):741-749.
[25] BADRA S, ANDERSSON KE, DEAN A, et al. Long-term structural and functional effects of autologous muscle precursor cell therapy in a nonhuman primate model of urinary sphincter deficiency. J Urol. 2013;190(5):1938-1945.
[26] MITTERBERGER M, PINGGERA GM, MARKSTEINER R, et al. Functional and histological changes after myoblast injections in the porcine rhabdosphincter. Eur Urol. 2007;52(6):1736-1743.
[27] WILLIAMS JK, ECKMAN D, DEAN A, et al. The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency. Stem Cells Transl Med. 2015;4(3):286-294.
[28] MITTERBERGER M, MARKSTEINER R, MARGREITER E, et al. Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. BJU Int. 2007;100(5):1081-1085.
[29] CARR LK, ROBERT M, KULTGEN PL, et al. Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol. 2013;189(2):595-601.
[30] PETERS KM, DMOCHOWSKI RR, CARR LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192(2):469-476.
[31] SÈBE P, DOUCET C, CORNU JN, et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study. Int Urogynecol J. 2011;22(2):183-189.
[32] BACAKOVA L, ZARUBOVA J, TRAVNICKOVA M, et al. Stem cells: their source, potency and use in regenerative therapies with focus on adipose- derived stem cells - a review. Biotechnol Adv. 2018;36(4):1111-1126.
[33] BAJEK A, OLKOWSKA J, WALENTOWICZ-SADŁECKA M, et al. Human Adipose-Derived and Amniotic Fluid-Derived Stem Cells: A Preliminary In Vitro Study Comparing Myogenic Differentiation Capability. Med Sci Monit. 2018;24:1733-1741.
[34] RAPOSIO E, BERTOZZI N. Isolation of Ready-to-Use Adipose-Derived Stem Cell (ASC) Pellet for Clinical Applications and a Comparative Overview of Alternate Methods for ASC Isolation. Curr Protoc Stem Cell Biol. 2017;41:1F.17.1-1F.17.12.
[35] KIM WS, PARK BS, SUNG JH, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci. 2007;48(1):15-24.
[36] BERTOZZI N, SIMONACCI F, GRIECO MP, et al. The biological and clinical basis for the use of adipose-derived stem cells in the field of wound healing. Ann Med Surg (Lond). 2017;20:41-48.
[37] RAPOSIO E, SIMONACCI F, PERROTTA RE. Adipose-derived stem cells: Comparison between two methods of isolation for clinical applications. Ann Med Surg (Lond). 2017;20:87-91.
[38] RAPOSIO E, BERTOZZI N, BONOMINI S, et al. Adipose-derived Stem Cells Added to Platelet-rich Plasma for Chronic Skin Ulcer Therapy. Wounds. 2016;28(4):126-131.
[39] FORCALES SV. Potential of adipose-derived stem cells in muscular regenerative therapies. Front Aging Neurosci. 2015;7:123.
[40] BOISSIER R, MAGALON J, SABATIER F, et al. Histological and Urodynamic Effects of Autologous Stromal Vascular Fraction Extracted from Fat Tissue with Minimal Ex Vivo Manipulation in a Porcine Model of Intrinsic Sphincter Deficiency. J Urol. 2016;196(3):934-942.
[41] SILWAL GAUTAM S, IMAMURA T, ISHIZUKA O, et al. Implantation of autologous adipose-derived cells reconstructs functional urethral sphincters in rabbit cryoinjured urethra. Tissue Eng Part A. 2014; 20(13-14):1971-1979.
[42] KUISMANEN K, SARTONEVA R, HAIMI S, et al. Autologous adipose stem cells in treatment of female stress urinary incontinence: results of a pilot study. Stem Cells Transl Med. 2014;3(8):936-941.
[43] ARJMAND B, SAFAVI M, HEIDARI R, et al. Concomitant Transurethral and Transvaginal-Periurethral Injection of Autologous Adipose Derived Stem Cells for Treatment of Female Stress Urinary Incontinence: A Phase One Clinical Trial. Acta Med Iran. 2017;55(6):368-374.
[44] IKEDA S, TSUJI S, OHAMA T, et al. Involvement of PP2A Methylation in the Adipogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cell. J Biochem. 2020 Jul 14:mvaa077. doi: 10.1093/jb/mvaa077. Online ahead of print.
[45] KONNO M, HAMABE A, HASEGAWA S, et al. Adipose-derived mesenchymal stem cells and regenerative medicine. Dev Growth Differ. 2013;55(3):309-318.
[46] WILLIAMS JK, DEAN A, LANKFORD S, et al. Determinates of muscle precursor cell therapy efficacy in a nonhuman primate model of intrinsic urinary sphincter deficiency. Stem Cell Res Ther. 2017;8(1):1.
[47] EBERLI D, ABOUSHWAREB T, SOKER S, et al. Muscle precursor cells for the restoration of irreversibly damaged sphincter function. Cell Transplant. 2012;21(9):2089-2098.
[48] POKRYWCZYNSKA M, ADAMOWICZ J, CZAPIEWSKA M, et al. Targeted therapy for stress urinary incontinence: a systematic review based on clinical trials. Expert Opin Biol Ther. 2016;16(2):233-242.
[49] LOUKOGEORGAKIS SP, DE COPPI P. Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications. Stem Cells. 2017;35(7):1663-1673.
[50] DE COPPI P, BARTSCH G JR, SIDDIQUI MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007;25(1): 100-106.
[51] JAIN M, MINOCHA E, TRIPATHY NK, et al. Comparison of the Cardiomyogenic Potency of Human Amniotic Fluid and Bone Marrow Mesenchymal Stem Cells. Int J Stem Cells. 2019;12(3):449-456.
[52] LIM JJ, JANG JB, KIM JY, et al. Human umbilical cord blood mononuclear cell transplantation in rats with intrinsic sphincter deficiency. J Korean Med Sci. 2010;25(5):663-670.
[53] BURDZINSKA A, DYBOWSKI B, ZARYCHTA-WIŚNIEWSKA W, et al. Intraurethral co-transplantation of bone marrow mesenchymal stem cells and muscle-derived cells improves the urethral closure. Stem Cell Res Ther. 2018;9(1):239.
[54] 刘湄漪,陈乃耀.间充质干细胞旁分泌作用的研究进展[J].中华细胞与干细胞杂志(电子版),2018,8(4):240-243.
[55] PERPIÑÁ-VICIANO C, IŞBILIR A, ZARCA A, et al. Kinetic Analysis of the Early Signaling Steps of the Human Chemokine Receptor CXCR4. Mol Pharmacol. 2020;98(2):72-87.
[56] ZAMBON JP, PATEL M, HEMAL A, et al. Nonhuman primate model of persistent erectile and urinary dysfunction following radical prostatectomy: Feasibility of minimally invasive therapy. Neurourol Urodyn. 2018;37(7):2141-2150.
[57] WILLIAMS JK, DEAN A, BADRA S, et al. Cell versus Chemokine Therapy in a Nonhuman Primate Model of Chronic Intrinsic Urinary Sphincter Deficiency. J Urol. 2016;196(6):1809-1815.
[58] CULENOVA M, ZIARAN S, DANISOVIC L. Cells Involved in Urethral Tissue Engineering: Systematic Review. Cell Transplant. 2019;28(9-10):1106-1115.
[59] ZHU Q, LI Q, NIU X, et al. Extracellular Vesicles Secreted by Human Urine-Derived Stem Cells Promote Ischemia Repair in a Mouse Model of Hind-Limb Ischemia. Cell Physiol Biochem. 2018;47(3):1181-1192.
[60] WU R, HUANG C, WU Q, et al. Exosomes secreted by urine-derived stem cells improve stress urinary incontinence by promoting repair of pubococcygeus muscle injury in rats. Stem Cell Res Ther. 2019;10(1):80.
|